TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more
TuHURA Biosciences Inc (HURA) - Net Assets
Latest net assets as of September 2025: $16.78 Million USD
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has net assets worth $16.78 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.70 Million) and total liabilities ($8.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.78 Million |
| % of Total Assets | 65.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | 37.93% |
| 10-Year Change | 200.36% |
| Growth Volatility | 1394.22 |
TuHURA Biosciences Inc - Net Assets Trend (2014–2025)
This chart illustrates how TuHURA Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TuHURA Biosciences Inc (2014–2025)
The table below shows the annual net assets of TuHURA Biosciences Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $14.59 Million | +1036.26% |
| 2024-06-30 | $-1.56 Million | -112.67% |
| 2023-06-30 | $12.30 Million | +1745.31% |
| 2022-06-30 | $-747.82K | -107.07% |
| 2021-06-30 | $10.58 Million | +3923.19% |
| 2020-06-30 | $263.00K | -86.63% |
| 2019-06-30 | $1.97 Million | -63.80% |
| 2018-06-30 | $5.44 Million | -17.38% |
| 2017-06-30 | $6.58 Million | +35.39% |
| 2016-06-30 | $4.86 Million | +691.46% |
| 2015-06-30 | $-821.49K | -0.43% |
| 2014-06-30 | $-817.98K | -- |
Equity Component Analysis
This analysis shows how different components contribute to TuHURA Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9526006300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $42.32K | 0.29% |
| Other Components | $125.68 Million | 861.15% |
| Total Equity | $14.59 Million | 100.00% |
TuHURA Biosciences Inc Competitors by Market Cap
The table below lists competitors of TuHURA Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
$57.66 Million |
|
UHT Unitech Co., Ltd.
TWO:6618
|
$57.70 Million |
|
Türk Traktör ve Ziraat Makineleri A.S
PINK:TTRKF
|
$57.71 Million |
|
PLIANT THERA.INC.DL-0001
F:9PT
|
$57.71 Million |
|
Nekkar Asa
OL:NKR
|
$57.62 Million |
|
Kestrel Group, Ltd.
NYSE:KG
|
$57.58 Million |
|
OXFORD METRICS LS-0025
F:RNI
|
$57.58 Million |
|
Pacific Petroleum Transportation JSC
VN:PVP
|
$57.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TuHURA Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,558,746 to 14,593,976, a change of 16,152,722.
- Net loss of 21,682,306 reduced equity.
- New share issuances of 5,000,000 increased equity.
- Other factors increased equity by 32,835,028.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.68 Million | -148.57% |
| Share Issuances | $5.00 Million | +34.26% |
| Other Changes | $32.84 Million | +224.99% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares TuHURA Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-06-30 | $-1930.01 | $2.08 | x |
| 2015-06-30 | $-1510.59 | $2.08 | x |
| 2016-06-30 | $7766.22 | $2.08 | x |
| 2017-06-30 | $9556.25 | $2.08 | x |
| 2018-06-30 | $4559.75 | $2.08 | x |
| 2019-06-30 | $1337.55 | $2.08 | x |
| 2020-06-30 | $44.07 | $2.08 | x |
| 2021-06-30 | $715.37 | $2.08 | x |
| 2022-06-30 | $-26.87 | $2.08 | x |
| 2023-06-30 | $265.83 | $2.08 | x |
| 2024-06-30 | $-2.07 | $2.08 | x |
| 2025-06-30 | $0.78 | $2.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TuHURA Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -148.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-148.57%) is above the historical average (-414.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.21 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.27 Million |
| 2016 | -182.45% | 0.00% | 0.00x | 1.31x | $-9.35 Million |
| 2017 | -122.85% | 0.00% | 0.00x | 1.20x | $-8.74 Million |
| 2018 | -204.93% | 0.00% | 0.00x | 1.30x | $-11.68 Million |
| 2019 | -409.05% | 0.00% | 0.00x | 2.05x | $-8.24 Million |
| 2020 | -3469.96% | 0.00% | 0.00x | 11.17x | $-9.15 Million |
| 2021 | -361.95% | 0.00% | 0.00x | 1.28x | $-39.36 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.94 Million |
| 2023 | -76.13% | 0.00% | 0.00x | 1.24x | $-10.60 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.16 Million |
| 2025 | -148.57% | 0.00% | 0.00x | 1.37x | $-23.14 Million |
Industry Comparison
This section compares TuHURA Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TuHURA Biosciences Inc (HURA) | $16.78 Million | 0.00% | 0.53x | $57.62 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |